Mer­ck KGaA con­tin­ues AI drug dis­cov­ery deal spree with Bi­olo­jic De­sign 

Mer­ck KGaA has tapped Is­rael biotech Bi­olo­jic De­sign to help cre­ate mul­ti-spe­cif­ic an­ti­bod­ies us­ing AI.

In the lat­est AI-dri­ven col­lab­o­ra­tion Mer­ck KGaA has an­nounced in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.